When should I use a standard C-reactive protein (CRP) assay versus a high-sensitivity C-reactive protein (hs-CRP) assay?

When to Use Standard CRP vs High-Sensitivity CRP

Use high-sensitivity CRP (hs-CRP) for cardiovascular risk assessment in primary prevention, particularly in intermediate-risk patients; use standard CRP for detecting acute inflammation, infection, and monitoring inflammatory conditions where CRP levels are expected to be >10 mg/L. 1

Clinical Context Determines Test Selection

Use hs-CRP When:

Cardiovascular Risk Stratification (Primary Prevention)

• Patients at intermediate cardiovascular risk (10-20% 10-year CHD risk) benefit most from hs-CRP measurement to guide further evaluation or intensification of therapy. 1
• hs-CRP should be measured twice, averaged, optimally 2 weeks apart, in metabolically stable patients without obvious infection or inflammation 1
• Risk categories are: low risk (<1.0 mg/L), average risk (1.0-3.0 mg/L), and high risk (>3.0 mg/L), corresponding to approximate population tertiles 1
• The high-risk tertile shows a 2-fold increase in relative risk compared to the low-risk tertile 1

Secondary Prevention/Prognostication

• hs-CRP may be useful for estimating prognosis in patients with stable coronary disease, acute coronary syndromes, or after percutaneous coronary intervention, though it should not determine whether to implement proven secondary prevention strategies 1

Important Caveats for hs-CRP:

• Do not use hs-CRP as an alternative to major risk factors for risk assessment 1
• If hs-CRP is ≥10 mg/L, search for an obvious source of infection or inflammation, discard that result, and remeasure in 2 weeks 1
• Serial testing of hs-CRP should not be used to monitor effects of treatment 1
• Population-wide screening with hs-CRP is not recommended as a public health measure 1

Use Standard CRP When:

Acute Inflammatory Conditions

• Acute bacterial infections typically show CRP elevations with median ~120 mg/L 2
• Inflammatory diseases demonstrate median CRP ~65 mg/L 2
• Post-surgical monitoring where CRP levels >100 mg/L are highly suggestive of bacterial etiology 3

Monitoring Active Inflammation

• Rising CRP after initial decline in post-surgical sepsis patients warrants immediate clinical reassessment 3
• Serial CRP measurements every 2-3 days until the trend clearly declines or source is identified 3
• Periprosthetic joint infections, where ESR and CRP together improve diagnostic accuracy (93% sensitivity, 100% specificity when both abnormal) 3

Solid Tumor Assessment

• Solid tumors can elevate CRP with median ~46 mg/L 2, 4
• However, approximately one-third of hospitalized cancer patients have CRP <10 mg/L, so normal CRP does not exclude malignancy 4

Technical Considerations

Modern Standard CRP Assays Are Highly Sensitive

• Contemporary standard CRP assays have lower detection limits of 0.3-0.6 mg/L, making them highly correlated with hs-CRP assays (R² = 0.98, kappa 0.87) 5
• Agreement between standard CRP and hs-CRP occurs in 91.4% of cases for cardiovascular risk stratification 5
• The average difference between standard CRP and hs-CRP is only 0.19 mg/L 5

Cost-Effectiveness

• Standard CRP assays are less expensive and provide online, real-time availability 6
• In settings where modern standard CRP assays are available (detection limit <1 mg/L), they may reasonably substitute for hs-CRP in cardiovascular risk assessment 5

Specific Disease Contexts Where hs-CRP Is Superior

Subclinical Inflammation Detection

• Ankylosing spondylitis and non-radiographic axial spondyloarthritis: hs-CRP correlates better with clinical disease activity parameters than standard CRP, especially in patients with negative routine CRP (<6 mg/L) 7
• Endometriosis: hs-CRP detects subclinical inflammation in 100% of samples vs 42.7% with classical CRP, with significantly increased levels in women with endometriosis during the luteal phase 8

Common Pitfalls to Avoid

• Do not reassure patients with clinically suspicious findings (e.g., suspicious lymph nodes) based solely on normal CRP, as approximately 33% of cancer patients have CRP <10 mg/L 4
• Do not use hs-CRP alone to make treatment decisions without assessing traditional cardiovascular risk factors first 1
• Do not attribute CRP values >10 mg/L solely to cardiovascular risk, as these levels can be associated with smoking, obesity, and other non-cardiovascular factors 2
• Do not postpone histologic investigation in suspicious clinical scenarios awaiting CRP elevation 4

Practical Algorithm

1. If assessing cardiovascular risk in primary prevention: Use hs-CRP in intermediate-risk patients (10-20% 10-year CHD risk), measured twice, 2 weeks apart, when metabolically stable 1

2. If evaluating acute infection, post-surgical complications, or active inflammatory disease: Use standard CRP, as levels will typically be >10 mg/L and standard assays are adequate 2, 3

3. If detecting subclinical inflammation in chronic inflammatory conditions: Use hs-CRP for superior sensitivity and correlation with disease activity 7, 8

4. If your laboratory's standard CRP assay has a detection limit <1 mg/L: It may substitute for hs-CRP in cardiovascular risk assessment, offering cost savings without sacrificing accuracy 5